Jessica Campbell
Family · Greenville, ALNPI 1144468851
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,704 of the $25,602 with a category attached, or 73.1%. Novo Nordisk accounts for 84.0% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2022 at $10,463 and has fallen 86.7% since, to $1,394 in 2025. Among family clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $72.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$22K
- AbbVie$925
- Lilly USA, LLC$729
- AstraZeneca$589
- GSK$249
- Bayer$248
- plus $1K from 20 others
What the payments were for
- Speaking & faculty fees$18,70473%
- Travel & lodging$1,2845%
- Food & beverage$5,55522%
- Education$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 88 | $21,507 |
| AbbVie | 71 | $925 |
| Lilly USA, LLC | 54 | $729 |
| AstraZeneca | 32 | $589 |
| GSK | 14 | $249 |
| Bayer | 13 | $248 |
| Axsome Therapeutics, Inc. | 10 | $218 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $153 |
| Pfizer | 8 | $142 |
| Boehringer Ingelheim | 8 | $121 |
| IBSA Pharma Inc. | 6 | $103 |
| Esperion Therapeutics, Inc. | 5 | $85 |
| Abbott | 5 | $83 |
| Dexcom, Inc. | 4 | $67 |
| Merck | 4 | $57 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $56 |
| Phathom Pharmaceuticals, Inc. | 4 | $54 |
| Mylan Specialty L.p. | 3 | $42 |
| Exact Sciences | 2 | $35 |
| Lundbeck LLC | 2 | $28 |
| Atland Pharmaceuticals, LLC | 1 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Novartis | 1 | $18 |
| Corcept Therapeutics | 1 | $16 |
| Amgen | 1 | $15 |
| Shield Therapeutics Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,602 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 217 | $266,720 |
| OzempicSemaglutide | 132 | $206,197 |
| JardianceEmpagliflozin | 87 | $116,582 |
| EliquisApixaban | 102 | $111,535 |
| RybelsusSemaglutide | 54 | $103,953 |
| FarxigaDapagliflozin Propanediol | 76 | $94,992 |
| LinzessLinaclotide | 52 | $53,415 |
| TrulicityDulaglutide | 50 | $52,438 |
| VraylarCariprazine Hcl | 22 | $44,977 |
| JanuviaSitagliptin Phosphate | 18 | $25,401 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $22,760 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $21,624 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $19,178 |
| TrulancePlecanatide | 11 | $15,499 |
| XareltoRivaroxaban | 17 | $14,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $729 | $319,158267 claims |
| Novo NordiskOzempic, Rybelsus | $21,507 | $310,150186 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $589 | $135,472135 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $121 | $126,232100 claims |
| PfizerEliquis | $142 | $111,535102 claims |
| AbbVieLinzess, Vraylar | $925 | $98,39274 claims |
| MerckJanuvia, Lagevrio (Eua) | $57 | $35,42435 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $249 | $31,14554 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $153 | $15,49911 claims |
| NovartisEntresto | $18 | $12,93524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.
Other family in Greenville
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
- Julia BettsHuntsville$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.